Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AARON L BOSTER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1760641740
CMS profile
80266
Location
COLUMBUS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$160,328.97

221 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 221 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AARON L BOSTER

NPI 1760641740 · CMS profile ID 80266

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

COLUMBUS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 221 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760641740?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AARON L BOSTER, NPI 1760641740, CMS profile ID 80266. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 221 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760641740?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). AARON L BOSTER, NPI 1760641740, CMS profile ID 80266. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 221 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760641740?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
AARON L BOSTER, NPI 1760641740, CMS profile ID 80266, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 221 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1760641740?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

221 matching records · $160,328.97 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 221 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 221.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $20.8708/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827823249 CMS
Mallinckrodt Hospital Products Inc. $10.9308/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845347629 CMS
Medtronic, Inc. $170.7208/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827386795 CMS
EMD Serono, Inc. $3,080.0007/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849153213 CMS
GENZYME CORPORATION $2,184.0007/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843600395 CMS
Merck KGaA $1,760.0007/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840490353 CMS
GENZYME CORPORATION $1,695.0007/26/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843600405 CMS
Novartis Pharmaceuticals Corporation $17.9407/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812614897 CMS
Allergan, Inc. $7.1807/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792713185 CMS
GENZYME CORPORATION $80.9307/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843600389 CMS
GENZYME CORPORATION $4,095.0007/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843600391 CMS
GENZYME CORPORATION $543.9307/22/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843600393 CMS
SANOFI-AVENTIS U.S. LLC $38.4507/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843600383 CMS
Genentech, Inc. $49.9507/21/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835884271 CMS
Genentech, Inc. $49.9507/21/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835884273 CMS
Genentech USA, Inc. $16.0907/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835884287 CMS
Genentech USA, Inc. $6.5507/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835884289 CMS
Mallinckrodt Hospital Products Inc. $28.1007/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845347627 CMS
Biogen, Inc. $88.6807/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827823239 CMS
Medtronic, Inc. $350.0007/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815498895 CMS
Genentech USA, Inc. $1,800.0007/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835884349 CMS
Novartis Pharmaceuticals Corporation $4.6807/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812614895 CMS
EMD Serono, Inc. $12.1207/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849197299 CMS
SANOFI-AVENTIS U.S. LLC $23.7307/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843600373 CMS
Merck KGaA $2,640.0007/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840490351 CMS
Mallinckrodt Hospital Products Inc. $8.6507/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845347625 CMS
Genentech USA, Inc. $1,800.0006/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835884347 CMS
EMD Serono, Inc. $1,100.0006/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849181963 CMS
Genentech USA, Inc. $101.7706/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835884291 CMS
Novartis Pharmaceuticals Corporation $6.2806/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812614893 CMS
Biogen, Inc. $19.6106/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827823251 CMS
Saol Therapeutics Inc. $16.5006/17/2021 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796759737 CMS
Saol Therapeutics Inc. $16.5006/17/2021 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796759739 CMS
SANOFI-AVENTIS U.S. LLC $42.4806/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843600361 CMS
EMD Serono, Inc. $75.0006/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849198489 CMS
EMD Serono, Inc. $3,080.0006/14/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849179261 CMS
EMD Serono, Inc. $5.7706/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849197285 CMS
Allergan, Inc. $9.3606/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792713183 CMS
EMD Serono, Inc. $70.5606/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849153209 CMS
Genentech USA, Inc. $25.0806/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835884345 CMS
EMD Serono, Inc. $440.0006/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849181273 CMS
Avanir Pharmaceuticals, Inc. $11.4206/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801029989 CMS
EMD Serono, Inc. $10.5706/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849190497 CMS
GENZYME CORPORATION $1,911.0006/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843600381 CMS
Mallinckrodt Hospital Products Inc. $33.1906/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845347623 CMS
Novartis Pharmaceuticals Corporation $3.5306/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812614891 CMS
Genentech USA, Inc. $23.5205/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835884283 CMS
Genentech USA, Inc. $4,800.0005/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835884329 CMS
Genentech USA, Inc. $15.3605/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835884331 CMS
Genentech USA, Inc. $497.1805/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835884333 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $287,258.51 280
PY2020 $174,597.94 167
PY2021 $160,328.97 221
PY2022 $212,711.10 288
PY2023 $246,406.33 244
PY2024 $54,821.63 101
PY2025 $64,166.10 67

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $802,667.61 73
PY2024 Principal investigator $728,487.44 35
PY2023 Principal investigator $1,117,042.57 37
PY2022 Recipient $1,250.00 1
PY2022 Principal investigator $1,111,928.74 26
PY2021 Recipient $1,250.00 1
PY2021 Principal investigator $647,645.22 21
PY2020 Recipient $3,855.13 10
PY2020 Principal investigator $524,890.20 5
PY2019 Recipient $12,429.57 33
PY2019 Principal investigator $183,673.10 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

73 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $130.00 12/22/2025 Non-covered Recipient Entity
Boster Research Center Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226124510
Principal investigator 1 GENZYME CORPORATION $480.00 12/22/2025 Non-covered Recipient Entity
Boster Research Center Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226124513
Principal investigator 1 GENZYME CORPORATION $24,662.60 12/22/2025 Non-covered Recipient Entity
Boster Research Center Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226124518
Principal investigator 1 GENZYME CORPORATION $160.00 12/22/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124521
Principal investigator 1 Genentech, Inc. $9,163.00 12/19/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581949
Principal investigator 1 Genentech, Inc. $39.00 12/15/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581953
Principal investigator 1 Hoffmann-La Roche Limited $3,270.00 12/01/2025 Non-covered Recipient Entity
BOSTER RESEARCH CENTER LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211581873
Principal investigator 1 Genentech, Inc. $6,231.00 11/25/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581941
Principal investigator 1 Genentech, Inc. $32.40 11/20/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581945
Principal investigator 1 Genentech, Inc. $16.20 11/18/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581937
Principal investigator 1 GENZYME CORPORATION $27,849.25 11/17/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124504
Principal investigator 1 GENZYME CORPORATION $27,742.15 11/17/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124508
Principal investigator 1 GENZYME CORPORATION $13,881.94 10/20/2025 Non-covered Recipient Entity
Boster Research Center Llc
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226124500
Principal investigator 1 Genentech, Inc. $8,593.00 10/15/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581934
Principal investigator 1 GENZYME CORPORATION $357.50 10/14/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124485
Principal investigator 1 GENZYME CORPORATION $80.00 10/14/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124491
Principal investigator 1 GENZYME CORPORATION $487.50 10/14/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124496
Principal investigator 1 Genentech, Inc. $108.00 09/25/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581916
Principal investigator 1 Genentech, Inc. $18.00 09/25/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581923
Principal investigator 1 GENZYME CORPORATION $10,626.80 09/22/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124480
Principal investigator 1 Genentech, Inc. $6,801.00 09/17/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581919
Principal investigator 1 GENZYME CORPORATION $80.00 09/03/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124462
Principal investigator 1 GENZYME CORPORATION $135,508.80 09/03/2025 Non-covered Recipient Entity
Boster Research Center Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226124476
Principal investigator 1 GENZYME CORPORATION $20.87 08/25/2025 Non-covered Recipient Entity
Boster Research Center Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226124466
Principal investigator 1 GENZYME CORPORATION $29.21 08/25/2025 Non-covered Recipient Entity
Boster Research Center Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226124472
Principal investigator 1 Genentech, Inc. $4,537.00 08/21/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581913
Principal investigator 1 GENZYME CORPORATION $120.00 08/18/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124456
Principal investigator 1 Genentech, Inc. $44.00 08/11/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581929
Principal investigator 1 GENZYME CORPORATION $21,053.10 08/04/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124451
Principal investigator 1 GENZYME CORPORATION $40.00 07/28/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124439
Principal investigator 1 GENZYME CORPORATION $120.00 07/28/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124442
Principal investigator 1 GENZYME CORPORATION $12,775.90 07/28/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124447
Principal investigator 1 Genentech, Inc. $21,546.00 07/21/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581908
Principal investigator 1 GENZYME CORPORATION $6,963.96 07/07/2025 Non-covered Recipient Entity
Boster Research Center Llc
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226124430
Principal investigator 1 GENZYME CORPORATION $29,100.70 07/02/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124426
Principal investigator 1 GENZYME CORPORATION $10,863.46 07/02/2025 Non-covered Recipient Entity
Boster Research Center Llc
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226124435
Principal investigator 1 Hoffmann-La Roche Limited $2,356.25 06/17/2025 Non-covered Recipient Entity
THE BOSTER CENTER FOR MULTIPLE SCLEROSIS
OPERETTA II Ocrelizumab Pediatric Phase III study No dispute reported 06/30/2026 1211664125
Principal investigator 1 GENZYME CORPORATION $19,792.20 06/16/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124410
Principal investigator 1 Genentech, Inc. $22.00 06/16/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581880
Principal investigator 1 GENZYME CORPORATION $2,100.00 05/27/2025 Non-covered Recipient Entity
The Boster Center For Multiple Sclerosis
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226107140
Principal investigator 1 Genentech, Inc. $21.50 05/21/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581876
Principal investigator 1 Genentech, Inc. $11,335.00 05/21/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581884
Principal investigator 1 GENZYME CORPORATION $40.00 05/19/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124416
Principal investigator 1 GENZYME CORPORATION $1,272.00 05/19/2025 Non-covered Recipient Entity
Boster Research Center Llc
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226124422
Principal investigator 1 GENZYME CORPORATION $40.00 04/28/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124397
Principal investigator 1 GENZYME CORPORATION $20.87 04/28/2025 Non-covered Recipient Entity
Boster Research Center Llc
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226124401
Principal investigator 1 GENZYME CORPORATION $20.87 04/28/2025 Non-covered Recipient Entity
Boster Research Center Llc
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226124406
Principal investigator 1 Genentech, Inc. $10.75 04/25/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581900
Principal investigator 1 Hoffmann-La Roche Limited $7,881.00 04/24/2025 Non-covered Recipient Entity
THE BOSTER CENTER FOR MULTIPLE SCLEROSIS
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211664116
Principal investigator 1 Hoffmann-La Roche Limited $884.00 04/24/2025 Non-covered Recipient Entity
THE BOSTER CENTER FOR MULTIPLE SCLEROSIS
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211664120
Principal investigator 1 Genentech, Inc. $21.60 04/21/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581892
Principal investigator 1 GENZYME CORPORATION $24,076.50 04/14/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124393
Principal investigator 1 GENZYME CORPORATION $1,973.70 04/07/2025 Non-covered Recipient Entity
Boster Research Center Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226124380
Principal investigator 1 GENZYME CORPORATION $1,272.00 04/02/2025 Non-covered Recipient Entity
The Boster Center For Multiple Sclerosis
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226107055
Principal investigator 1 GENZYME CORPORATION $488.00 04/02/2025 Non-covered Recipient Entity
The Boster Center For Multiple Sclerosis
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226107065
Principal investigator 1 Genentech, Inc. $39,816.00 04/02/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581904
Principal investigator 1 Amgen Inc. $62,280.07 04/01/2025 Non-covered Recipient Entity
THE BOSTER CENTER FOR MULTIPLE SCLEROSIS
A Randomized, Double Blind, Parallel Group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692, and Ocrevus (Ocrelizumab) in Subjects with Relapsing Remitting Multiple Sclerosis No dispute reported 06/30/2026 1246649379
Principal investigator 1 GENZYME CORPORATION $200.00 03/24/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124377
Principal investigator 1 Genentech, Inc. $10.00 03/20/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581895
Principal investigator 1 GENZYME CORPORATION $2,544.00 03/17/2025 Non-covered Recipient Entity
The Boster Center For Multiple Sclerosis
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226107050
Principal investigator 1 GENZYME CORPORATION $9,911.99 03/17/2025 Non-covered Recipient Entity
Boster Research Center Llc
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226124373
Principal investigator 1 GENZYME CORPORATION $10,161.80 03/10/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124353
Principal investigator 1 GENZYME CORPORATION $20.87 03/10/2025 Non-covered Recipient Entity
Boster Research Center Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226124368
Principal investigator 1 GENZYME CORPORATION $50,771.70 03/04/2025 Non-covered Recipient Entity
Boster Research Center Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226124365
Principal investigator 1 GENZYME CORPORATION $40.00 03/04/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124389
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,502.25 02/25/2025 Non-covered Recipient Entity
THE BOSTER CENTER FOR MS
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190311503
Principal investigator 1 Hoffmann-La Roche Limited $3,901.00 02/13/2025 Non-covered Recipient Entity
THE BOSTER CENTER FOR MULTIPLE SCLEROSIS
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211664113
Principal investigator 1 GENZYME CORPORATION $12,669.00 02/10/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124358
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,684.70 01/31/2025 Non-covered Recipient Entity
THE BOSTER CENTER FOR MULTIPLE SCLEROSIS
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190310641
Principal investigator 1 GENZYME CORPORATION $120.00 01/27/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124361
Principal investigator 1 GENZYME CORPORATION $28,391.05 01/13/2025 Non-covered Recipient Entity
Boster Research Center Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124384
Principal investigator 1 Genentech, Inc. $20.87 01/13/2025 Non-covered Recipient Entity
BOSTER RESEARCH CTR LLC THE BOSTER CTR FOR MULTIPLE SCLEROSIS LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211581888
Principal investigator 1 Amgen Inc. $115,461.73 01/09/2025 Non-covered Recipient Entity
THE BOSTER CENTER FOR MULTIPLE SCLEROSIS
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis No dispute reported 06/30/2026 1246649383